Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
Open Access
- 1 February 2020
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (2) , 488-497
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 MutationsPLOS ONE, 2013
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerEuropean Journal of Cancer, 2013
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast CancerCancer Discovery, 2012
- Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both EnzymesJournal of Biological Chemistry, 2012
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal CancerJournal of Clinical Oncology, 2009
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Hypoxia-Induced Down-regulation of BRCA1 Expression by E2FsCancer Research, 2005
- Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer CellsMolecular and Cellular Biology, 2004